PRTN3 and rheumatoid arthritis: The data presented herein, are indicative of key differences in the underlying immune mechanisms and disease pathogenesis of ACPA+ and ACPA− RA and raise the potential for a treat to target approach based on stratification of the patients on ACPA status.